Isavuconazonium generic?

Is Isavuconazonium Available as a Generic?

Isavuconazonium is not currently available as a generic medication [1]. It is marketed under the brand name Cresemba, manufactured by Astellas Pharma [2].

What is Isavuconazonium Used For?

Isavuconazonium is an antifungal medication used to treat invasive aspergillosis and invasive mucormycosis [3]. It works by inhibiting the growth of fungi [3].

How Does Isavuconazonium Work?

Isavuconazonium is a prodrug that is converted into its active form, isavuconazole, in the body [3]. Isavuconazole disrupts the fungal cell membrane by inhibiting the enzyme lanosterol 14α-demethylase, which is essential for ergosterol synthesis [3].

When Might a Generic Version Become Available?

The availability of a generic version of a drug typically occurs after the expiration of relevant patents and market exclusivity periods [4]. Specific patent and exclusivity information for isavuconazonium would determine when generic manufacturers could potentially enter the market [4].

What Are the Risks Associated with Isavuconazonium?

Common side effects of isavuconazonium can include nausea, vomiting, diarrhea, headache, and liver enzyme elevations [3]. More serious adverse events can also occur [3]. Patients should discuss potential risks with their healthcare provider [3].

Are There Other Medications for Invasive Fungal Infections?

Other antifungal medications are available to treat invasive fungal infections, including other azoles (e.g., fluconazole, voriconazole) and echinocandins [5]. The choice of treatment depends on the specific fungal pathogen, patient factors, and local resistance patterns [5].

Sources:

[1] https://www.goodrx.com/isavuconazonium-chloride
[2] https://www.ncbi.nlm.nih.gov/books/NBK547970/
[3] https://www.mayoclinic.org/drugs-supplements/isavuconazonium-oral-route-injection-route/proper-use/drg-20158931
[4] https://www.fda.gov/drugs/abbreviated-new-drug-applications-and-505b2-applications/patent-and-exclusivity-information-generic-drugs
[5] https://www.idsociety.org/practice-guideline/aspergillosis/